Design Therapeutics Analyst Ratings
Design Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 79.36% | RBC Capital | $7 → $4 | Maintains | Sector Perform |
| 08/15/2023 | 169.05% | Wedbush | → $6 | Downgrades | Outperform → Neutral |
| 08/15/2023 | 169.05% | SVB Leerink | → $6 | Downgrades | Outperform → Market Perform |
| 08/15/2023 | 213.89% | RBC Capital | $23 → $7 | Downgrades | Outperform → Sector Perform |
| 05/10/2023 | 931.34% | RBC Capital | $24 → $23 | Maintains | Outperform |
| 05/10/2023 | 751.98% | Wedbush | $20 → $19 | Maintains | Outperform |
| 05/04/2023 | — | Goldman Sachs | Upgrades | Sell → Neutral | |
| 03/15/2023 | 976.18% | RBC Capital | → $24 | Reiterates | → Outperform |
| 12/09/2022 | 886.5% | SVB Leerink | $30 → $22 | Maintains | Outperform |
| 12/08/2022 | 976.18% | RBC Capital | $29 → $24 | Maintains | Outperform |
| 08/09/2022 | 1065.87% | Wedbush | $21 → $26 | Maintains | Outperform |
| 06/10/2022 | 841.66% | Wedbush | → $21 | Initiates Coverage On | → Outperform |
| 05/24/2022 | 169.05% | Goldman Sachs | $8 → $6 | Maintains | Sell |
| 05/10/2022 | 1245.23% | SVB Leerink | $36 → $30 | Maintains | Outperform |
| 05/02/2022 | 1245.23% | RBC Capital | → $30 | Initiates Coverage On | → Outperform |
| 01/19/2022 | 348.41% | Goldman Sachs | → $10 | Initiates Coverage On | → Sell |
| 04/20/2021 | 1514.28% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 04/20/2021 | 1155.55% | Goldman Sachs | → $28 | Initiates Coverage On | → Neutral |
| 04/20/2021 | 1783.32% | Piper Sandler | → $42 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/14/2023 | 79.36% | 加拿大皇家銀行資本 | 7 美元 → 4 美元 | 維護 | 行業表現 |
| 08/15/2023 | 169.05% | Wedbush | → 6 美元 | 降級 | 跑贏大盤 → 中性 |
| 08/15/2023 | 169.05% | SVB Leerink | → 6 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 08/15/2023 | 213.89% | 加拿大皇家銀行資本 | 23 美元 → 7 美元 | 降級 | 跑贏大盤 → 行業表現 |
| 05/10/2023 | 931.34% | 加拿大皇家銀行資本 | 24 美元 → 23 美元 | 維護 | 跑贏大盤 |
| 05/10/2023 | 751.98% | Wedbush | 20 美元 → 19 美元 | 維護 | 跑贏大盤 |
| 05/04/2023 | — | 高盛 | 升級 | 賣出 → 中立 | |
| 03/15/2023 | 976.18% | 加拿大皇家銀行資本 | → 24 美元 | 重申 | → 跑贏大盤 |
| 2022 年 9 月 12 日 | 886.5% | SVB Leerink | 30 美元 → 22 美元 | 維護 | 跑贏大盤 |
| 2022 年 8 月 12 日 | 976.18% | 加拿大皇家銀行資本 | 29 美元 → 24 美元 | 維護 | 跑贏大盤 |
| 08/09/2022 | 1065.87% | Wedbush | 21 美元 → 26 美元 | 維護 | 跑贏大盤 |
| 06/10/2022 | 841.66% | Wedbush | → 21 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2022 年 5 月 24 日 | 169.05% | 高盛 | 8 美元 → 6 美元 | 維護 | 賣出 |
| 05/10/2022 | 1245.23% | SVB Leerink | 36 美元 → 30 美元 | 維護 | 跑贏大盤 |
| 05/02/2022 | 1245.23% | 加拿大皇家銀行資本 | → 30 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2022 年 1 月 19 日 | 348.41% | 高盛 | → 10 美元 | 啓動覆蓋範圍開啓 | → 賣出 |
| 04/20/2021 | 1514.28% | SVB Leerink | → 36 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 04/20/2021 | 1155.55% | 高盛 | → 28 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 04/20/2021 | 1783.32% | 派珀·桑德勒 | → 42 美元 | 啓動覆蓋範圍開啓 | → 超重 |
What is the target price for Design Therapeutics (DSGN)?
Design Therapeutics（DSGN）的目標價格是多少？
The latest price target for Design Therapeutics (NASDAQ: DSGN) was reported by RBC Capital on November 14, 2023. The analyst firm set a price target for $4.00 expecting DSGN to rise to within 12 months (a possible 79.36% upside). 10 analyst firms have reported ratings in the last year.
加拿大皇家銀行資本於2023年11月14日公佈了Design Therapeutics（納斯達克股票代碼：DSGN）的最新目標股價。該分析公司將目標股價定爲4.00美元，預計DSGN將在12個月內升至12個月內（可能上漲79.36％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for Design Therapeutics (DSGN)?
分析師對Design Therapeutics（DSGN）的最新評級是多少？
The latest analyst rating for Design Therapeutics (NASDAQ: DSGN) was provided by RBC Capital, and Design Therapeutics maintained their sector perform rating.
加拿大皇家銀行資本對Design Therapeutics（納斯達克股票代碼：DSGN）的最新分析師評級由加拿大皇家銀行資本提供，Design Therapeutics維持其行業表現評級。
When is the next analyst rating going to be posted or updated for Design Therapeutics (DSGN)?
Design Therapeutics（DSGN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Design Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Design Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Design Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Design Therapeutics的最新評級是在2023年11月14日發佈的，因此您應該預計下一個評級將在2024年11月14日左右公佈。
Is the Analyst Rating Design Therapeutics (DSGN) correct?
分析師評級 Design Therapeutics (DSGN) 是否正確？
While ratings are subjective and will change, the latest Design Therapeutics (DSGN) rating was a maintained with a price target of $7.00 to $4.00. The current price Design Therapeutics (DSGN) is trading at is $2.23, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Design Therapeutics（DSGN）評級保持不變，目標股價爲7.00美元至4.00美元。Design Therapeutics（DSGN）目前的交易價格爲2.23美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。